Allergan reports increased sales

Allergan, Inc., reported $1.6 billion in total product net sales for the quarter ended March 31, an increase of 13 percent compared to the first quarter of 2013.

"In the first quarter Allergan delivered strong sales and earnings per share growth above the high end of our expectations," said David E.I. Pyott, Allergan's chairman of the Board and CEO. "Furthermore, we are pleased with the continuing strength of our growing markets around the world and our market share gains in many businesses."

Allergan expects total product net sales between $1.7 billion and $1.8 billion for the second quarter of 2014 and, for the full year of 2014, total product net sales between $6.8 billion and $7 billion, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business. For the full year, this includes Alphagan franchise product net sales between $460 million and $490 million, Lumigan franchise product net sales between $590 million and $620 million, and Latisse product net sales between $100 million and $110 million.